- Home
- FEMY vs BCAB Comparison
FEMY vs BCAB Comparison
Compare FEMY & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- BCAB
- Stock Information
- Founded
- FEMY 2004
- BCAB 2007
- Country
- FEMY United States
- BCAB United States
- Employees
- FEMY 71
- BCAB N/A
- Industry
- FEMY Medical/Dental Instruments
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- FEMY Health Care
- BCAB Health Care
- Exchange
- FEMY Nasdaq
- BCAB Nasdaq
- Market Cap
- FEMY 23.1M
- BCAB 21.0M
- IPO Year
- FEMY 2021
- BCAB 2020
- Fundamental
- Price
- FEMY $0.71
- BCAB $0.37
- Analyst Decision
- FEMY Strong Buy
- BCAB Hold
- Analyst Count
- FEMY 3
- BCAB 3
- Target Price
- FEMY $7.33
- BCAB $1.00
- AVG Volume (30 Days)
- FEMY 238.0K
- BCAB 639.1K
- Earning Date
- FEMY 08-08-2025
- BCAB 08-07-2025
- Dividend Yield
- FEMY N/A
- BCAB N/A
- EPS Growth
- FEMY N/A
- BCAB N/A
- EPS
- FEMY N/A
- BCAB N/A
- Revenue
- FEMY $1,887,016.00
- BCAB $11,000,000.00
- Revenue This Year
- FEMY $283.83
- BCAB N/A
- Revenue Next Year
- FEMY $161.03
- BCAB N/A
- P/E Ratio
- FEMY N/A
- BCAB N/A
- Revenue Growth
- FEMY 98.61
- BCAB N/A
- 52 Week Low
- FEMY $0.69
- BCAB $0.24
- 52 Week High
- FEMY $1.80
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- FEMY 34.99
- BCAB 49.36
- Support Level
- FEMY $0.72
- BCAB $0.34
- Resistance Level
- FEMY $1.00
- BCAB $0.40
- Average True Range (ATR)
- FEMY 0.06
- BCAB 0.03
- MACD
- FEMY -0.01
- BCAB 0.00
- Stochastic Oscillator
- FEMY 0.89
- BCAB 58.73
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.